Metabolic
Tirzepatide
Tirzepatide (dual GIP/GLP-1 receptor agonist)
Tirzepatide is a synthetic 39-amino-acid peptide engineered from the native GIP sequence with structural modifications conferring agonism at both the GIP and GLP-1 receptors. A C20 fatty diacid moiety supports albumin binding and extended half-life. Its research interest lies substantially in the question of whether dual incretin agonism produces effects distinguishable from GLP-1 monoagonism.
Research applications
- Dual incretin receptor signaling and biased agonism studies
- Comparative studies against selective GLP-1 agonists
- cAMP accumulation and β-arrestin recruitment assays
- Adipose and hepatic metabolic pathway research
Storage
Store lyophilized powder at -20°C protected from light. Reconstituted solution stable at 2-8°C for up to 30 days.
Reconstitution
Reconstitute with bacteriostatic water directed down the vial wall. Swirl gently — do not shake or vortex.
Published literature
2,273 papers indexed on PubMed for Tirzepatide. Showing 6, reviews first.
- 01Tirzepatide for overweight and obesity management
Hamza M et al. · Expert Opin Pharmacother · 2025
- 02Tirzepatide: A Review in Type 2 Diabetes
France NL, Syed YY · Drugs · 2024
- 03Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER)
Wilson L et al. · Diabetes Obes Metab · 2026
- 04Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Aronne LJ et al. · N Engl J Med · 2025
- 05Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
Rodriguez PJ et al. · JAMA Intern Med · 2024
- 06Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis
Zeng Q et al. · Front Endocrinol (Lausanne) · 2023
Indexed from PubMed, 2026-07-19. We link to sources rather than reproducing them.
Related compounds
Semaglutide
5–20mg · COA published
Long-acting GLP-1 receptor agonist studied extensively for incretin pathway signaling and glucose regulation in preclinical models.
- CAS
- 910463-68-2
- MW
- 4113.58
- Purity
- Per published certificate
Retatrutide
10–30mg · COA published
Triple agonist at GIP, GLP-1, and glucagon receptors — among the most actively studied compounds in current metabolic research.
- CAS
- 2381089-83-2
- MW
- 4731.32
- Purity
- Per published certificate
Cagrilintide
10mg · COA published
Long-acting amylin analog studied at calcitonin and amylin receptors — a satiety pathway mechanistically distinct from incretin agonism.
- CAS
- 1415456-99-3
- MW
- 4409
- Purity
- Per published certificate
AOD-9604
5mg · COA published
C-terminal fragment of human growth hormone studied for lipolytic activity without the growth-promoting effects of the full hormone.
- CAS
- 221231-10-3
- MW
- 1815.08
- Purity
- Per published certificate
How Tirzepatide compares
Side-by-side against the compounds researchers most often weigh it against, with price per milligram, mechanism and the published certificate for each.
Tirzepatide vs Retatrutide
Dual versus triple agonism. The question is what glucagon receptor activation adds beyond incretin signaling.
Semaglutide vs Tirzepatide
Single versus dual incretin receptor engagement — the central comparison in current metabolic pharmacology.
AOD-9604 vs Tirzepatide
Cagrilintide vs Tirzepatide
Tirzepatide
From $89